Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05524974 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 1, 2022 (before its estimated September 1, 2024 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
To evaluate the clinical efficacy of camrelizumab, apatinib Mesylate and nab-paclitaxel combined with oxplatin and S-1 in the neoadjuvant treatment of locally advanced gastric cancer with different genotypes
Trial Details
NCT Number NCT05524974
Lead Sponsor Fujian Medical University
Conditions
(from sponsor)		 Locally Advanced Gastric Cancer
Enrollment 203 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov